EE40 Cost-Effectiveness of GLP-1 Receptor Agonists Versus Long-Acting Insulins in Type 2 Diabetes From the Healthcare Sector Perspective: A Model-Based Analysis Using Real-World Data

Abstract

Most previous cost-effectiveness analyses (CEAs) of glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus long-acting insulins (LAIs) utilized the effectiveness parameters which were derived from clinical trials and not country/population-specific, and it may thus have limited study generalizability to real-world settings. We conducted a model-based CEA of GLP-1RAs versus LAIs from the Taiwan healthcare sector perspective using data from a real-world Taiwanese cohort of type 2 diabetes (T2D) to inform real-world decision-making.